{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:57Z","timestamp":1772165697911,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03846-x","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:51:36Z","timestamp":1732787496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The outcome of thrombotic microangiopathy in kidney transplant recipients"],"prefix":"10.1186","volume":"25","author":[{"given":"Kanza","family":"Haq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Obaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Maggiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Alachkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"8","key":"3846_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMra2014530","volume":"385","author":"S Hariharan","year":"2021","unstructured":"Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med. 2021Aug 19;385(8):729\u201343.","journal-title":"N Engl J Med"},{"issue":"8","key":"3846_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","volume":"347","author":"JL Moake","year":"2002","unstructured":"Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002Aug 22;347(8):589\u2013600.","journal-title":"N Engl J Med"},{"key":"3846_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.642864","volume":"8","author":"A \u00c1vila","year":"2021","unstructured":"\u00c1vila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne). 2021;8: 642864.","journal-title":"Front Med (Lausanne)"},{"key":"3846_CR4","doi-asserted-by":"crossref","unstructured":"Zarifian A, Meleg-Smith S, O\u2019donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999 Jun;55(6):2457\u201366.","DOI":"10.1046\/j.1523-1755.1999.00492.x"},{"issue":"5","key":"3846_CR5","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","volume":"42","author":"JC Reynolds","year":"2003","unstructured":"Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis. 2003Nov;42(5):1058\u201368.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"3846_CR6","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","volume":"10","author":"AA Satoskar","year":"2010","unstructured":"Satoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant. 2010Aug;10(8):1804\u201311.","journal-title":"Am J Transplant"},{"issue":"4","key":"3846_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","volume":"14","author":"G Bayer","year":"2019","unstructured":"Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, et al. Etiology and Outcomes of Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019Apr 5;14(4):557\u201366.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"3846_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5500\/wjt.v8.i5.122","volume":"8","author":"F Abbas","year":"2018","unstructured":"Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplant. 2018Sep 10;8(5):122\u201341.","journal-title":"World J Transplant"},{"key":"3846_CR9","doi-asserted-by":"crossref","unstructured":"Caires RA, Marques IDB, Repizo LP, Sato V a. H, Carmo LPF, Machado DJB, et al. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc. 2012 Oct;44(8):2388\u201390.","DOI":"10.1016\/j.transproceed.2012.07.039"},{"issue":"2","key":"3846_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","volume":"41","author":"J Schwimmer","year":"2003","unstructured":"Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003Feb;41(2):471\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"3846_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","volume":"19","author":"C Ponticelli","year":"2006","unstructured":"Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation. Transpl Int. 2006Oct;19(10):789\u201394.","journal-title":"Transpl Int"},{"issue":"4","key":"3846_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/ajkd.2000.17690","volume":"36","author":"PT Pham","year":"2000","unstructured":"Pham PT, Peng A, Wilkinson AH, Gritsch HA, Lassman C, Pham PC, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000Oct;36(4):844\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3846_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000321328","volume":"32","author":"K De Keyzer","year":"2010","unstructured":"De Keyzer K, Van Laecke S, Peeters P, Vanholder R. De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss. Am J Nephrol. 2010;32(5):491\u20136.","journal-title":"Am J Nephrol"},{"issue":"3","key":"3846_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","volume":"60","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001Sep;60(3):831\u201346.","journal-title":"Kidney Int"},{"issue":"2","key":"3846_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009Feb;4(2):481\u2013508.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3846_CR16","doi-asserted-by":"crossref","unstructured":"Liptak P, Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol. 2006 Jul;2(7):398\u2013404; quiz following 404.","DOI":"10.1038\/ncpneph0225"},{"issue":"5","key":"3846_CR17","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1172\/JCI116440","volume":"91","author":"DM Lanese","year":"1993","unstructured":"Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest. 1993May;91(5):2144\u20139.","journal-title":"J Clin Invest"},{"key":"3846_CR18","doi-asserted-by":"crossref","unstructured":"English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 1987 Jul;44(1):135\u201341.","DOI":"10.1097\/00007890-198707000-00027"},{"issue":"8","key":"3846_CR19","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","volume":"8","author":"M Le Quintrec","year":"2008","unstructured":"Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008Aug;8(8):1694\u2013701.","journal-title":"Am J Transplant"},{"issue":"3","key":"3846_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.hoc.2015.02.002","volume":"29","author":"CJ Sperati","year":"2015","unstructured":"Sperati CJ, Moliterno AR. Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome. Hematol Oncol Clin North Am. 2015Jun;29(3):541\u201359.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"3846_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12882-020-01847-0","volume":"21","author":"S Kant","year":"2020","unstructured":"Kant S, Bhalla A, Alasfar S, Alachkar N. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience. BMC Nephrol. 2020May 20;21(1):189.","journal-title":"BMC Nephrol"},{"issue":"1","key":"3846_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrneph.2010.155","volume":"7","author":"J Zuber","year":"2011","unstructured":"Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fr\u00e9meaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011Jan;7(1):23\u201335.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"3846_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5527\/wjn.v2.i3.56","volume":"2","author":"M Salvadori","year":"2013","unstructured":"Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol. 2013Aug 6;2(3):56\u201376.","journal-title":"World J Nephrol"},{"key":"3846_CR24","doi-asserted-by":"crossref","unstructured":"Lahlou A, Lang P, Charpentier B, Barrou B, Glotz D, Baron C, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coop\u00e9ratif de l\u2019Ile-de-France (GCIF). Medicine (Baltimore). 2000 Mar;79(2):90\u2013102.","DOI":"10.1097\/00005792-200003000-00003"},{"issue":"4","key":"3846_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","volume":"27","author":"J Zuber","year":"2013","unstructured":"Zuber J, Le Quintrec M, Morris H, Fr\u00e9meaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013Oct;27(4):117\u201325.","journal-title":"Transplant Rev (Orlando)"},{"issue":"5","key":"3846_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/01.TP.0000085083.74065.1B","volume":"76","author":"MA Artz","year":"2003","unstructured":"Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LAH, Wetzels JFM. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation. 2003Sep 15;76(5):821\u20136.","journal-title":"Transplantation"},{"issue":"11","key":"3846_CR27","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","volume":"23","author":"C Loirat","year":"2008","unstructured":"Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008Nov;23(11):1957\u201372.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"3846_CR28","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007Aug;18(8):2392\u2013400.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3846_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2215\/CJN.00050505","volume":"1","author":"E Bresin","year":"2006","unstructured":"Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006Jan;1(1):88\u201399.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3846_CR30","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1053\/j.ajkd.2016.10.006","volume":"68","author":"MA Lusco","year":"2016","unstructured":"Lusco MA, Fogo AB, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Thrombotic Microangiopathy. Am J Kidney Dis. 2016Dec;68(6):e33\u20134.","journal-title":"Am J Kidney Dis"},{"key":"3846_CR31","doi-asserted-by":"crossref","unstructured":"Chatelet V, Fr\u00e9meaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009 Nov;9(11):2644\u20135.","DOI":"10.1111\/j.1600-6143.2009.02817.x"},{"key":"3846_CR32","doi-asserted-by":"crossref","unstructured":"Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ, Global aHUS Registry. Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney Int Rep. 2019 Mar;4(3):434\u201346.","DOI":"10.1016\/j.ekir.2018.11.010"},{"issue":"11","key":"3846_CR33","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","volume":"98","author":"D Matar","year":"2014","unstructured":"Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014Dec 15;98(11):1205\u201312.","journal-title":"Transplantation"},{"issue":"8","key":"3846_CR34","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","volume":"25","author":"N Alachkar","year":"2012","unstructured":"Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int. 2012Aug;25(8):e93-95.","journal-title":"Transpl Int"},{"key":"3846_CR35","first-page":"52","volume":"1","author":"S Alasfar","year":"2014","unstructured":"Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne). 2014;1:52.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"3846_CR36","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/ASN.2019040331","volume":"30","author":"J Zuber","year":"2019","unstructured":"Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, et al. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol. 2019Dec;30(12):2449\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"3846_CR37","doi-asserted-by":"crossref","unstructured":"Opelz G, D\u00f6hler B, Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation. 2008 Mar 15;85(5):661\u20136.","DOI":"10.1097\/TP.0b013e3181661695"},{"issue":"2","key":"3846_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/08860220701810547","volume":"30","author":"MR Ardalan","year":"2008","unstructured":"Ardalan MR, Shoja MM, Tubbs RS, Etemadi J, Esmaili H, Khosroshahi HT. Thrombotic microangiopathy in the early post-renal transplant period. Ren Fail. 2008;30(2):199\u2013203.","journal-title":"Ren Fail"},{"issue":"12","key":"3846_CR39","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/tri.13022","volume":"30","author":"CM Legendre","year":"2017","unstructured":"Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommel\u00e9 \u00c5, et al. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int. 2017Dec;30(12):1275\u201383.","journal-title":"Transpl Int"},{"issue":"11","key":"3846_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188155","volume":"12","author":"LGM de Andrade","year":"2017","unstructured":"de Andrade LGM, Contti MM, Nga HS, Bravin AM, Takase HM, Viero RM, et al. Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS ONE. 2017;12(11): e0188155.","journal-title":"PLoS ONE"},{"issue":"12","key":"3846_CR41","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1097\/TP.0000000000001909","volume":"101","author":"C Levi","year":"2017","unstructured":"Levi C, Fr\u00e9meaux-Bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, et al. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation. 2017Dec;101(12):2924\u201330.","journal-title":"Transplantation"},{"issue":"4","key":"3846_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/ctr.12170","volume":"27","author":"S Koppula","year":"2013","unstructured":"Koppula S, Yost SE, Sussman A, Bracamonte ER, Kaplan B. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. Clin Transplant. 2013;27(4):591\u20137.","journal-title":"Clin Transplant"},{"issue":"2","key":"3846_CR43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1600-6143.2008.02482.x","volume":"9","author":"N Ashman","year":"2009","unstructured":"Ashman N, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant. 2009Feb;9(2):424\u20137.","journal-title":"Am J Transplant"},{"key":"3846_CR44","doi-asserted-by":"crossref","unstructured":"Teixeira CM, Tedesco Silva Junior H, Moura LAR de, Proen\u00e7a HM de S, de Marco R, Gerbase de Lima M, et al. Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes. PLoS One. 2020;15(1):e0227445.","DOI":"10.1371\/journal.pone.0227445"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03846-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:03:19Z","timestamp":1732788199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03846-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3846"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03846-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4688690\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee is the Johns Hopkins Hospital\u2019s Institutional Review Board. This is a retrospective study, data were collected from the electronic medical records, consents were waived by Johns Hopkins Hospital\u2019s Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"433"}}